Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
BLCO Stock Forecast 2026-2027
$15.18
Current Price
$5.41B
Market Cap
Buy 5
Hold 7
Sell 1
Wall St Analyst Ratings
Distance to BLCO Price Targets
+38.3%
To High Target of $21.00
+18.6%
To Median Target of $18.00
+5.4%
To Low Target of $16.00
BLCO Price Momentum
+1.3%
1 Week Change
-6.2%
1 Month Change
+26.7%
1 Year Change
-11.1%
Year-to-Date Change
-19.7%
From 52W High of $18.92
+32.7%
From 52W Low of $11.44
📊 TOP ANALYST CALLS
Did BLCO Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Bausch + Lomb is one of their latest high-conviction picks.
Latest BLCO Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, BLCO has a neutral consensus with a median price target of $18.00 (ranging from $16.00 to $21.00). The overall analyst rating is Buy (7.1/10). Currently trading at $15.18, the median forecast implies a 18.6% upside. This outlook is supported by 5 Buy, 7 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Yi Chen at HC Wainwright & Co., projecting a 38.3% upside. Conversely, the most conservative target is provided by Vijay Kumar at Evercore ISI Group, suggesting a 5.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BLCO Analyst Ratings
5
Buy
7
Hold
1
Sell
BLCO Price Target Range
Low
$16.00
Average
$18.00
High
$21.00
Current: $15.18
Latest BLCO Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BLCO.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 30, 2026 | Evercore ISI Group | Vijay Kumar | In-Line | Maintains | $16.00 |
| Apr 6, 2026 | Evercore ISI Group | In-Line | Maintains | $N/A | |
| Feb 23, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 19, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Feb 19, 2026 | Barclays | Equal-Weight | Maintains | $N/A | |
| Feb 19, 2026 | Stifel | Hold | Maintains | $N/A | |
| Feb 19, 2026 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Feb 17, 2026 | Stifel | Hold | Maintains | $N/A | |
| Jan 5, 2026 | Evercore ISI Group | In-Line | Downgrade | $N/A | |
| Dec 2, 2025 | Morgan Stanley | Overweight | Upgrade | $N/A | |
| Nov 14, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Nov 14, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Oct 31, 2025 | Barclays | Equal-Weight | Maintains | $N/A | |
| Oct 31, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Oct 30, 2025 | JP Morgan | Neutral | Maintains | $N/A | |
| Oct 30, 2025 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Oct 30, 2025 | Wells Fargo | Equal-Weight | Maintains | $N/A | |
| Oct 30, 2025 | Raymond James | Outperform | Reiterates | $N/A | |
| Oct 7, 2025 | Evercore ISI Group | Outperform | Maintains | $N/A | |
| Oct 1, 2025 | Goldman Sachs | Neutral | Initiates | $N/A |
Bausch + Lomb Corporation (BLCO) Competitors
The following stocks are similar to Bausch + Lomb based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
BLCO
Bausch + Lomb
mkt cap
5.51B
Bausch + Lomb Corporation (BLCO) Financial Data
Bausch + Lomb Corporation has a market capitalization of $5.41B with a P/E ratio of -14.9x. The company generates $5.21B in trailing twelve-month revenue with a -4.2% profit margin.
Revenue growth is +9.4% quarter-over-quarter, while maintaining an operating margin of +4.7% and return on equity of -3.3%.
Valuation Metrics
Market Cap
$5.41B
Enterprise Value
$10.39B
P/E Ratio
-14.9x
PEG Ratio
0.2x
Price/Sales
1.0x
Growth & Margins
Revenue Growth (YoY)
+9.4%
Gross Margin
+61.2%
Operating Margin
+4.7%
Net Margin
-4.2%
EPS Growth
+9.4%
Financial Health
Cash/Price Ratio
+5.0%
Current Ratio
1.5x
Debt/Equity
78.6x
ROE
-3.3%
ROA
+1.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Bausch + Lomb Corporation (BLCO) Business Model
About Bausch + Lomb Corporation
What They Do
Develops and markets eye health products.
Business Model
The company generates revenue through the development, manufacture, and sale of contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices. By catering to both consumers and medical professionals, it diversifies its income streams and addresses various market needs in vision care.
Additional Information
Bausch + Lomb is headquartered in Rochester, New York, and is committed to innovation in eye health through extensive research and development. Its global presence allows it to meet the increasing demand for advanced vision care solutions.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
13,500
CEO
Mr. Brenton L. Saunders J.D.
Country
Canada
IPO Year
2022
Website
www.bausch.comBausch + Lomb Corporation (BLCO) Latest News & Analysis
Latest News
Quick Summary
Bausch + Lomb Corporation (BLCO) has discussed its Project Halo and advancements in myopia control within its vision care segment.
Why It Matters
Bausch + Lomb's advancements in myopia control could enhance their market position, potentially increasing revenue and attracting investment, impacting stock performance positively.
Source: Seeking Alpha
Market Sentiment:
Positive
Bausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United States
8 days ago
Quick Summary
Bausch + Lomb launched Blink Triple Care Preservative Free eye drops in the U.S., offering long-lasting relief for dry eyes without preservatives, in a multi-dose bottle.
Why It Matters
Bausch + Lomb's launch of preservative-free eye drops addresses a growing demand in eye care, potentially boosting sales and market share, positively impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Bausch + Lomb Corporation announced the election of 10 directors at its 2026 annual meeting, with Eduardo Alfonso, M.D. receiving 331.6 million votes in favor.
Why It Matters
The election of directors at Bausch + Lomb signals governance stability, influencing investor confidence and potential future performance of the company.
Source: Business Wire
Market Sentiment:
Neutral
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
19 days ago
Quick Summary
Bausch + Lomb's CEO Brent Saunders and CMO Yehia Hashad will speak at the Goldman Sachs Global Healthcare Conference on June 9, 2026, at 1:20 p.m. ET; a live webcast will be available.
Why It Matters
Bausch + Lomb's participation in a major healthcare conference highlights its strategic visibility and potential for growth, which can impact stock performance and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Consumer sentiment is low at 53.3 in March 2026, prompting retail investors to seek defensive stocks that can grow amid tighter household budgets.
Why It Matters
Low consumer sentiment indicates reduced spending, prompting investors to seek defensive stocks that can sustain growth amid economic uncertainty. This shift can impact market dynamics and sector performance.
Source: 24/7 Wall Street
Market Sentiment:
Neutral
Quick Summary
Bausch + Lomb will host a webinar on June 1, 2026, at 1:00 p.m. ET to discuss its product pipeline, featuring insights from R&D executives.
Why It Matters
Bausch + Lomb's focus on R&D and product pipeline insights signals potential growth and innovation, which could enhance market position and attract investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About BLCO Stock
What is Bausch + Lomb Corporation's (BLCO) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Bausch + Lomb Corporation (BLCO) has a median price target of $18.00. The highest price target is $21.00 and the lowest is $16.00.
Is BLCO stock a good investment in 2026?
According to current analyst ratings, BLCO has 5 Buy ratings, 7 Hold ratings, and 1 Sell ratings. The stock is currently trading at $15.18. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for BLCO stock?
Wall Street analysts predict BLCO stock could reach $18.00 in the next 12 months. This represents a 18.6% increase from the current price of $15.18. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bausch + Lomb Corporation's business model?
The company generates revenue through the development, manufacture, and sale of contact lenses, lens care products, ophthalmic pharmaceuticals, and surgical devices. By catering to both consumers and medical professionals, it diversifies its income streams and addresses various market needs in vision care.
What is the highest forecasted price for BLCO Bausch + Lomb Corporation?
The highest price target for BLCO is $21.00 from Yi Chen at HC Wainwright & Co., which represents a 38.3% increase from the current price of $15.18.
What is the lowest forecasted price for BLCO Bausch + Lomb Corporation?
The lowest price target for BLCO is $16.00 from Vijay Kumar at Evercore ISI Group, which represents a 5.4% increase from the current price of $15.18.
What is the overall BLCO consensus from analysts for Bausch + Lomb Corporation?
The overall analyst consensus for BLCO is neutral. Out of 13 Wall Street analysts, 5 rate it as Buy, 7 as Hold, and 1 as Sell, with a median price target of $18.00.
How accurate are BLCO stock price projections?
Stock price projections, including those for Bausch + Lomb Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 9, 2026 10:54 AM UTC